Drug Candidate for Treatment of Acute Heart Failure
APD418 is a first-in-class β3-adrenergic receptor (AdrR) antagonist and cardiac myotrope designed to regulate myofilament calcium sensitivity in order to improve contractility without inducing the serious adverse events associated with currently available inotropes. APD418 is in early-stage clinical development for patients with acute heart failure, or AHF.
About Acute Heart Failure
AHF is broadly defined as a rapid onset of new or worsening signs and symptoms of HF. It is a potentially life-threatening condition, requiring hospitalization, and emergency treatment is aimed predominantly at managing fluid overload and achieving hemodynamic stability. In most cases, hospitalization for AHF results when the neurohormonal compensatory mechanism, which acts to maintain hemodynamic stability in chronic heart failure, are inadequate.
Status
| Drug Candidate |
Disease Area |
Target |
Status |
| APD418 |
Acute heart failure |
β3 adrenergic receptor
(AdrR) antagonist |
Ph 1 |
|
| Retained Rights |
| Worldwide |
|
APD418 has not been approved by the US Food and Drug Administration or any other regulatory agency.
| Drug Candidate |
Disease Area |
Status |
| APD418 |
Acute heart failure
β3 adrenergic receptor
(AdrR) antagonist |
Ph 1 |
|
| Retained Rights |
| Worldwide |
|
Last updated as of 8/7/19